You are currently viewing Pα+ Psychedelic Bulletin #156: Canada’s First Published Psilocybin Trial; University of Maryland Joins Terran’s Complaint Against Compass

Pα+ Psychedelic Bulletin #156: Canada’s First Published Psilocybin Trial; University of Maryland Joins Terran’s Complaint Against Compass

Post published:February 19, 2024
Post category:Psychedelic Bulletin / Pα+

This content is for Pα+ Subscribers

This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.

PsychedeliCare Launches First European Citizens’ Initiative Demanding Political Action on Psychedelic-Assisted TherapiesJanuary 14, 2025
From 14 January 2025, the PsychedeliCare European Citizens’ Initiative (ECI) has 12 months to gather one million signatures in support of its request that the European Commission take meaningful action to fund, standardise and reschedule psychedelics for medical use.
Pα+ Psychedelic Bulletin #185: Joe Rogan on Ibogaine; Wisconsin Medicaid to Cover IV Ketamine for Depression; Inside the Plan to Make Lykos MAPS AgainJanuary 11, 2025
This Issue: Joe Rogan on Ibogaine: Rick Perry and Bryan Hubbard Appear in Two-Hour Interview • On Psychedelic Lobbying • Neumora’s Kappa Opioid Receptor Drug for Depression Fails in Phase 3 • Wisconsin’s Medicaid System to Cover IV Ketamine for Depression • Inside the Plan to Make Lykos MAPS Again • Tacoma Set to Vote on Psychedelic Decrim. • APA Special Issue, APA Workshops and Webinars • and more...
Billionaire Investor Antonio Gracias Plots $100M Lykos Takeover with Doblin’s BackingJanuary 10, 2025
This latest twist in the Lykos Therapeutics saga threatens a major overhaul of the company’s strategy and direction, with Musk ally and billionaire investor Antonio Gracias appearing to want to take the company back toward its nonprofit drug development roots and a more Doblinite philosophy. Now, the company’s board must decide whether to stick with its current lead investor, Helena, or accept Gracias’ proposal.
From Fringe to Focus: APA’s American Journal of Psychiatry Publishes Special Issue on PsychedelicsJanuary 7, 2025
The American Journal of Psychiatry’s January issue is devoted entirely to psychedelics, providing an overview of some of the key methodological challenges and future directions for research and potential roll-out to a broad audience of psychiatrists and beyond. Backed by the imprimatur of its publisher, the American Psychiatric Association, the issue has been viewed as a welcome stamp of legitimacy to the field.
Natural Medicine Advisory Bulletin 15: A Duplicitous DecemberJanuary 6, 2025
As Colorado’s regulated psychedelics (or, ‘natural medicine’) program opens to applications, Vicente LLP review the latest developments which include an apparent eleventh-hour rule change by the Department of Regulatory Agencies which significantly limits the scope for at-home facilitation and raises questions about the viability of microdosing under the program.

Pα+ Psychedelic Bulletin #156: Canada’s First Published Psilocybin Trial; University of Maryland Joins Terran’s Complaint Against Compass

This content is for Pα+ Subscribers

Psychedelic Alpha

Quick Links

Newsletter

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

This content is for Pα+ Subscribers

You Might Also Like

What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 2)

Psychedelic Bulletin: DEA Moves to Schedule 5 Tryptamines; Eleusis Unveils SPAC; COMPASS Seeks LSD Patents

Psychedelic Bulletin #117 – A Deep Dive Into Psilocybin for Alcohol Use Disorder; Former MindMed CMO Alleges IP Was Syphoned off to Competitor; ARK Discusses Psychedelics

Psychedelic Alpha

Quick Links

Newsletter

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights